A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera

Hemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV).OBJECTIVESHemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV).We analyzed the characteristics of hemorrhagic events in 267 patients with PV.ME...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hematology (Luxembourg) 2024-12, Vol.29 (1), p.2427905
Hauptverfasser: Furuya, Chiho, Hashimoto, Yoshinori, Morishita, Soji, Fukuda, Yasutaka, Inano, Tadaaki, Ochiai, Tomonori, Shirane, Shuichi, Edahiro, Yoko, Araki, Marito, Ando, Miki, Komatsu, Norio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV).OBJECTIVESHemorrhagic events are a rare but potentially fatal complication in patients with polycythemia vera (PV).We analyzed the characteristics of hemorrhagic events in 267 patients with PV.METHODSWe analyzed the characteristics of hemorrhagic events in 267 patients with PV.A median follow-up of 4.8 years revealed that 23 (8.6%) hemorrhagic events occurred. Significantly more hemorrhagic events occurred in younger patients aged below 60 years (n = 72) than in older patients aged 60 years or above (n = 191) (n = 12 [16.7%] vs. n = 11 [5.8%], respectively, P = 0.012). In univariate analysis among the younger patients, white blood cell (WBC) count ≥ 15 × 109/L (hazard ratio [HR] = 7.746, 95% confidence interval [CI] 2.082-28.830, P = 0.002), palpable splenomegaly (HR = 5.629, 95% CI 1.193-26.550, P = 0.029), and JAK2V617F allele burden ≥ 80% (HR = 22.850, 95% CI 2.885-181.00, P = 0.003) were associated with an increased risk of hemorrhagic events. In multivariate analysis, JAK2V617F allele burden ≥ 80% (HR = 9.394, 95% CI 1.046-84.380, P = 0.046) was a significant risk factor.RESULTSA median follow-up of 4.8 years revealed that 23 (8.6%) hemorrhagic events occurred. Significantly more hemorrhagic events occurred in younger patients aged below 60 years (n = 72) than in older patients aged 60 years or above (n = 191) (n = 12 [16.7%] vs. n = 11 [5.8%], respectively, P = 0.012). In univariate analysis among the younger patients, white blood cell (WBC) count ≥ 15 × 109/L (hazard ratio [HR] = 7.746, 95% confidence interval [CI] 2.082-28.830, P = 0.002), palpable splenomegaly (HR = 5.629, 95% CI 1.193-26.550, P = 0.029), and JAK2V617F allele burden ≥ 80% (HR = 22.850, 95% CI 2.885-181.00, P = 0.003) were associated with an increased risk of hemorrhagic events. In multivariate analysis, JAK2V617F allele burden ≥ 80% (HR = 9.394, 95% CI 1.046-84.380, P = 0.046) was a significant risk factor.There is an increased risk of hemorrhagic events after diagnosis in younger PV patients with a high JAK2V617F allele burden, high WBC count or palpable splenomegaly. It is important to consider treatment options that aim to avoid hemorrhagic events by reducing the JAK2V617F allele burden in younger PV patients.CONCLUSIONSThere is an increased risk of hemorrhagic events after diagnosis in younger PV patients with a high JAK2V617F allele burden, high WBC count or palpable splen
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2024.2427905